Bank of America Merrill Lynch Form 38.5 (b) - AbbVie (6222D)
20 February 2020 - 10:04PM
UK Regulatory
TIDMTTM
RNS Number : 6222D
Bank of America Merrill Lynch
20 February 2020
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED
INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader Bank of America, N.A., Proprietary
Company dealt in AbbVie Inc
-----------------------------------
Class of relevant security to which the Common - US00287Y1091
dealings being disclosed relate(Note 1)
-----------------------------------
Date of dealing 19/02/2020
-----------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common US00287Y1091
Long Short
------------------- --------------------
Number % Number %
---------- ------- ---------- --------
(1) Relevant securities 2,004,861 0.136% 2,376,392 0.161 %
---------- ------- ---------- --------
(2) Derivatives (other than options): 3,282,042 0.222% 2,081,630 0.141%
---------- ------- ---------- --------
(3) Options and agreements to purchase/sell: 0 0% 0 0%
---------- ------- ---------- --------
Total 5,286,903 0.357% 4,458,022 0.301%
---------- ------- ---------- --------
(b) Interests and short positions in relevant securities
of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long Short
------------ ------------
Number % Number %
------- --- ------- ---
(1) Relevant securities 0 0% 0 0%
------- --- ------- ---
(2) Derivatives (other than options): 0 0% 0 0%
------- --- ------- ---
(3) Options and agreements to purchase/sell: 0 0% 0 0%
------- --- ------- ---
Total 0 0% 0 0%
------- --- ------- ---
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 93 93.61 USD
------------------------------ ------------------------
Purchase 91 94.14 USD
------------------------------ ------------------------
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 59 93.42 USD
------------------------------ ------------------------
Sale 93 93.61 USD
------------------------------ ------------------------
Sale 708 93.8 USD
------------------------------ ------------------------
Sale 210 94.34 USD
------------------------------ ------------------------
Sale 300 94.345 USD
------------------------------ ------------------------
Sale 124 94.37 USD
------------------------------ ------------------------
Sale 75 94.39 USD
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 5) (Note 6) (Note 4)
N/A N/A N/A N/A
---------------------- ------------------------------ ---------------
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry date Option money paid/ received
name, selling, securities price e.g. American, per unit (Note 4)
e.g. call purchasing, to which European
option varying the option etc
etc. relates (Note
7)
N/A N/A N/A N/A N/A N/A N/A
------------- --------------- --------- ---------------- ------------ ------------------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 4)
N/A N/A N/A
---------------------- --------------------
(d) Other dealings (including transactions in respect
of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7) (if applicable) (Note 4)
N/A N/A N/A
--------- ---------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 20/02/2020
Contact name Tolu Tade
------------------------
Telephone number +44207 996 3410
------------------------
Name of offeree/offeror with which connected AbbVie Inc
------------------------
Nature of connection (Note 9) Advisor to - AbbVie Inc
------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEURRARROUUUAR
(END) Dow Jones Newswires
February 20, 2020 06:04 ET (11:04 GMT)